Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

Rhea-AI Summary

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) will have its CEO, Roni Mamluk, present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 9:00 am ET. Ayala is focused on developing small molecule therapeutics for rare and aggressive cancers. Their lead candidates, AL101 and AL102, are in various clinical trials targeting cancers like Adenoid Cystic Carcinoma and Triple Negative Breast Cancer. Both products have received FDA designations to expedite their development. The live webcast can be accessed on Ayala's website, with a replay available for 90 days.

REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET.

A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

 

FAQ

When will Ayala Pharmaceuticals present at the Ladenburg Thalmann Healthcare Conference?

Ayala Pharmaceuticals will present on July 13, 2021, at 9:00 am ET.

Who is the CEO of Ayala Pharmaceuticals?

The CEO of Ayala Pharmaceuticals is Roni Mamluk.

What are the main product candidates of Ayala Pharmaceuticals?

Ayala Pharmaceuticals is developing AL101 and AL102, targeting various aggressive cancers.

What cancers are targeted by Ayala's AL101 and AL102?

AL101 and AL102 target cancers such as Adenoid Cystic Carcinoma and Triple Negative Breast Cancer.

How can I access the presentation from Ayala Pharmaceuticals' conference?

The presentation can be accessed via a live webcast on Ayala's website, with a replay available for approximately 90 days.